News
UK fertility start-up bags £145,000 investment
Myma Medical’s automated process aims to reduce the reliance on personal skill and increase success rates
The Liverpool City Region Combined Authority’s innovation commercialisation organisation LYVA Labs has invested £145,000 in fertility start-up Myma Medical to support couples struggling to conceive.
Infertility is the most common healthcare condition for 30-40 year olds, affecting around three and a half million people in the UK and 186 million worldwide.
Using automated technology, Myma Medical aims to improve success rates for people struggling with infertility by removing the current manual process and replacing it with an automated machine.
Currently, the process of physically taking the best sperm available to fertilise eggs by manual injection only has a 30 per cent success rate and is subject to human error. Myma Medical’s automated process aims to reduce the reliance on personal skill and increase success rates.
The automation process will also aim to eliminate the need for multiple procedures. These are often needed due to the low success rate, which comes at the cost of £10,000-12,000 per cycle.
“Myma Medical is a brilliant, innovative start-up with a model to significantly enhance the experiences of people struggling with their fertility,” said Lorna Green, CEO of LYVA Labs.
“So many of us are touched by fertility issues in our lives, either personally or through our communities so I am incredibly proud to bring a business like this to our ever-evolving region.”
She added: “I’m also pleased to see that again; we are using the Combined Authorities’ regional funding and support via LYVA Labs to establish a new company in the region and leverage national sources of innovation funding.
“It is vital we continue to support this approach to future-proof the investment cycles of early-stage businesses.”
Steve Rotheram, mayor of the Liverpool City Region, said: “People from the Liverpool City Region have got the talent, ambition and creativity to rival anywhere else in the world. But for too long, their potential has gone unfulfilled because of a lack of opportunities and investment. I launched LYVA Labs to help fix that.
“With nearly £11m of investment, we’re helping to turn great ideas into successful businesses, creating jobs, economic growth and prosperity for local residents.
“It’s fantastic to see this latest investment supporting a business that will not only generate new employment but deliver potentially life-changing support to families.”
Yash Khandhia , CEO of Myma Medical said: “We are excited to bring this innovative, game-changing technology to the fertility market to enhance the outcome of the treatments while saving money for the couples and improving their physiological and physical conditions.
“This technology is built through a great team effort over nearly a decade of fundamental and translational research.”
LYVA Labs has previously invested an initial £106,000 into Myma Medical, matched by a £390,000 Innovate UK SMART grant.
In its earlier years, the project secured financial support, totalling £351,000 from various scholarships, the Medical Research Council (MRC), Engineering and Physical Science Research Council (EPSRC), and ICURe (Innovate UK).
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Pregnancy
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur7 days agoUS startup builds wearable hormone tracker
-
Wellness3 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
Menopause2 weeks agoStudy reveals gap between perimenopause expectations and experience
-
Fertility6 days agoFrance urges 29-year-olds to start families now






